Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Clinical Genitourinary Cancer|March 12, 2018
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder CarcinomaJohannes Breyer, Ralph M Wirtz, Philipp Erben, et al.
Cancer|June 22, 2010
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyGiuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, et al.
Translational Oncology|March 26, 2017
High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder CancerDanijel Sikic, Johannes Breyer, Arndt Hartmann, et al.
Urologic Oncology|November 18, 2018
Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomyThomas Martini, Jakob Heinkele, Roman Mayr, et al.
Urologic Oncology|July 31, 2021
High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancerDanijel Sikic, Markus Eckstein, Veronika Weyerer, et al.
Translational Oncology|March 5, 2019
Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent CohortsDanijel Sikic, Ralph M Wirtz, Sven Wach, et al.
Life (Basel, Switzerland)|July 2, 2021
High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder CancerDanijel Sikic, Helge Taubert, Ralph M Wirtz, et al.
Scientific Reports|May 26, 2021
The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinomaStefan Porubsky, Malin Nientiedt, Maximilian C Kriegmair, et al.
Anticancer Research|December 30, 2022
Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory <i>In Silico</i> AnalysisManuel Neuberger, Lisa Frey, Katja Nitschke, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Clinical Genitourinary Cancer|March 12, 2018
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder CarcinomaJohannes Breyer, Ralph M Wirtz, Philipp Erben, et al.
Cancer|June 22, 2010
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice dailyGiuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, et al.
Translational Oncology|March 26, 2017
High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder CancerDanijel Sikic, Johannes Breyer, Arndt Hartmann, et al.
Urologic Oncology|November 18, 2018
Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomyThomas Martini, Jakob Heinkele, Roman Mayr, et al.
Urologic Oncology|July 31, 2021
High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancerDanijel Sikic, Markus Eckstein, Veronika Weyerer, et al.
Translational Oncology|March 5, 2019
Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent CohortsDanijel Sikic, Ralph M Wirtz, Sven Wach, et al.
Life (Basel, Switzerland)|July 2, 2021
High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder CancerDanijel Sikic, Helge Taubert, Ralph M Wirtz, et al.
Scientific Reports|May 26, 2021
The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinomaStefan Porubsky, Malin Nientiedt, Maximilian C Kriegmair, et al.
Anticancer Research|December 30, 2022
Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory <i>In Silico</i> AnalysisManuel Neuberger, Lisa Frey, Katja Nitschke, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Pageof 13